Market Analysis: Global Cluster Headache Drug Market

Global cluster headache drug market is expected to grow at a substantial CAGR of in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. This rise in market value can be attributed to the increasing prevalence of cluster headaches, growing geriatric population, development in the healthcare expenditure and the government support for the research & development for new and better treatment have fueled the market growth.

Key market players in the global cluster headaches market are F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc, AstraZeneca, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, TrioxBio Inc, Aurobindo Pharma, Endo Pharmaceuticals Inc, WOCKHARDT, Shanghai Soho Yiming Pharmaceutical Co., Ltd, Chengdu Tiantaishan pharmaceutical Co.,Ltd,  electroCore, Inc, Autonomic Technologies, Inc, WINSTON PHARMACEUTICALS, Inc, CAPNIA, Inc and few others.

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cluster-headache-drug-market

Market Definition: Global Cluster Headache Drug Market

Cluster headache is also known as Horton’s syndrome is characterized by a series of relatively short but severe pain on one side of the head every day for weeks or months at a time. Headaches occur in form of clusters which means bouts of frequent attacks which may last from weeks to months and followed by long periods of relief. Cluster headaches occur at the same time each year because of their seasonal nature. Symptoms include nasal discharge, redness of eyes and excessive tearing.

The prevalence rate of cluster headache is less than 1percent and mostly affects men. The attacks can begin at any age, although they usually occur between the ages of 20 and 40 years. The lifetime prevalence of cluster headache for adults of all ages was 124 per 100,000 or approximately 0.1 percent.

Market Drivers

Increasing prevalence of cluster headaches and migraine is driving the growth of this market
Increased television viewing and computer usage is also acting as a driver for the market
Growing geriatric population is propelling the market growth
Application of latest technologies in the health care industry can also act as a market driver

Market Restraints

Lack of awareness amongst people and healthcare providers about cluster headaches is hampering the market growth.
Increasing measure by government to lessen healthcare expenditure is also restricting the growth for the market
Unfavorable health care policies will also hamper the market growth
Segmentation: Global Cluster Headache Drug Market

By Types

Episodic
Chronic

By Mechanism of Action

Corticosteroids
Ergot alkaloids
Local Anesthetics
Calcium Channel Blockers
Triptans
Lithium Carbonate
Anti-Seizures

By Drugs Type

Fast-Acting Drugs
Sumatriptan
Dihydroergotamine
Octreotide
Lidocaine
Long-Term Drugs
VerapamilLithobid
Divalproex
Short-Term Drugs
Ergotamine
Prednisone

By Diagnosis

Neurological Examination
MRI
CT Scan

By Treatment

Medication
Surgery

By Route of Administration

Oral
Topical
Intravenous
Others

By End-Users

Hospitals
Homecare
Specialty Clinics
Others

By Geography

North America
U.S.
Canada
Mexico
Europe
Germany
Italy
U.K.
France
Spain
Netherlands
Belgium
Switzerland
Turkey
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
South Korea
Australia
Singapore
Malaysia
Thailand
Indonesia
Philippines
Rest of Asia Pacific
South America
Brazil
Rest of South America
Middle East & Africa
South Africa
Rest of Middle East & Africa

Get TOC of Full Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-cluster-headache-drug-market

Key Developments in the Market:

In June 2019, Eli Lilly and Company received the US FDA approval for Emgality (Galcanezumab). This drug became the first drug to gain U.S. approval for decreasing the frequency of episodic cluster headache attacks. It belongs to a new class of drugs called CGRP inhibitors that are used to prevent migraines or reduce their frequency
In April 2017, electroCore, Inc received the US FDA approval for gammaCore device, a non-invasive vagus nerve stimulator aimed to treat pain associated with episodic cluster headache in adult patients. Gammacore the first and only FDA-approved device for the prevention of cluster headache. It is a safe and effective treatment when compared to other treatments

Competitive Analysis:

Global cluster headaches drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of cluster headaches drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.